FDA approves Anktiva for non-muscle-invasive bladder cancer

Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care

The Supreme Court last week upended one of the underpinnings of administrative law by weakening the authority of federal health agencies to rely on technical expertise as they regulate medical products, issue coverage decisions, and respond to public health crises.

July 05, 2024

Vol.50 No.27

By Matthew Bin Han Ong

Conversation with The Cancer Letter

Georgetown’s Zachary Baron on the post-Chevron era: We need guardrails about when agency expertise should be cast aside

The Supreme Court struck down the Chevron doctrine, removing one of the foundational principles of administrative law and upending the way federal agencies rely on technical subject-matter expertise. What comes next?

July 05, 2024

Vol.50 No.27

By Matthew Bin Han Ong

Drugs & Targets

FDA grants Fast Track designation to Syncromune Inc. for drug-device combo for solid tumors in mCRPC

FDA granted Fast Track designation to Syncromune Inc., a clinical-stage biopharmaceutical company, for SYNC-T SV-102 therapy, Syncromune’s lead candidate for the treatment of patients with metastatic castrate-resistant prostate cancer.

July 05, 2024

Vol.50 No.27

White House

At White House forum, Bertagnolli, Califf, Wegrzyn call for greater innovation in clinical trials

Leaders of three health agencies presented new initiatives focused on patient-centered research, diversity in clinical trial enrollment, and innovation in clinical research.

June 28, 2024

Vol.50 No.26

By McKenzie Prillaman

In Brief

Steinhart, Foisey, Ganguly, Yamada-Hunter receive PICI Early Career Researcher awards

Zachary SteinhartMaxwell FoiseyDebolina GangulySean Yamada-HunterThe Parker Institute for Cancer Immunotherapy, a collaborative consortium of the world’s leading immuno-oncology experts, named its 2024 class of Early Career Researcher awardees.

June 28, 2024

Vol.50 No.26

In Brief

Noam Auslander receives $600K grant to identify connections between gut microbial genes and melanoma immunotherapy

The Wistar Institute’s Noam Auslander, assistant professor in the Molecular and Cellular Oncogenesis Program at the Ellen and Ronald Caplan Cancer Center, was awarded a $600,000 Women Scientists Innovation Award for Cancer Research grant from the V Foundation for Cancer Research.

June 28, 2024

Vol.50 No.26

FDA approves Anktiva for non-muscle-invasive bladder cancer

YOU MAY BE INTERESTED IN

Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care

Georgetown’s Zachary Baron on the post-Chevron era: We need guardrails about when agency expertise should be cast aside

FDA grants Fast Track designation to Syncromune Inc. for drug-device combo for solid tumors in mCRPC

At White House forum, Bertagnolli, Califf, Wegrzyn call for greater innovation in clinical trials

Steinhart, Foisey, Ganguly, Yamada-Hunter receive PICI Early Career Researcher awards

Noam Auslander receives $600K grant to identify connections between gut microbial genes and melanoma immunotherapy

Renew today!

Subscriber content

Login